leadf
logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy making significant headway at its Cheshire assembly facility

"Assembly activities in Daresbury have recently resumed with the view of assembling our first machine and having the infrastructure in place to cater for future demand," said CEO Nicolas Serandour

Advanced Oncotherapy PLC -
Pictured is a mock-up of the patient treatment area

Advanced Oncotherapy PLC (LON:AVO), the maker of next-generation proton therapy systems, said assembly activities at its Cheshire facility have resumed.

In an update, the company said it has received all bespoke and high precision accelerating structures for its game-changing LIGHT technology, adding that it was expecting the delivery of further supporting equipment in line with its completion plan.

The company told investors that “clinical use discussions” were continuing with the University Hospitals Birmingham NHS Foundation Trust (UHB), the London Clinic and the Mediterranean Hospital ahead of the installation of their LIGHT systems.

UHB was preparing to upload LIGHT beam data into its treatment planning systems (TPS) and is working with AVO to plan for the initial patient indications, it added.

The Cleveland Clinic, meanwhile, has been using the LIGHT TPS software for a two-year study to evaluate the “target conformity of proton mini-beams in comparison with X-ray stereotactic body radiation therapy and stereotactic radiosurgery”.

In a comprehensive rundown of its activities, AVO said the assembly site is ready to support the ultra-high vacuum tests and the high-voltage conditioning of the accelerating structures. This will prepare them for use in delivering the proton beams and will also allow it to assemble additional LIGHT systems.

The company also said the first beam diagnostic test benches have been installed at its Cheshire lab, while the powering sources for the inductive output tubes have been successfully tested and delivered. The first series of the magnets, which steer the accelerator beam towards the treatment room, have also arrived on-site. 

In the update, the market was also told:

  • Building requirements and building interfaces for the patient treatment area at the assembly have been finalised
  • Work on the safety systems for connecting the patient treatment area with the LIGHT system is ongoing
  • The machine installation process has been optimised, which will reduce the start-up time
  • Enhanced documentation has been completed which will speed up the installation of the patient positioning system
  • Upgraded versions of the oncology information system and the treatment session manager have been received
  • An upgraded version of the treatment planning system software has been installed

AVO chief executive, Nicolas Serandour, said: “We are grateful for the support of our team and suppliers who have shown greater flexibility during the pandemic and the support of our financing partners, such as VDL and Nerano Pharma, who have provided the debt facilities to support our continuing work on the LIGHT system."

Quick facts: Advanced Oncotherapy PLC

Price: 32.5 GBX

LSE:AVO
Market: LSE
Market Cap: £108.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read